Indicator | Description |
---|---|
F_0a | Multidisciplinary tumour boards assess the completeness of the diagnostics |
F_1 | The percentage of deaths within one year from the diagnosis of a malignant neoplasm, correlated to tumour stage |
F_2 | The percentage of deaths within 30 days from the date of surgery, correlated to tumour stage |
F_3 | Percentage of deaths within 30 days from the end of chemotherapy, correlated to tumour stage |
F_4 | Percentage of deaths within 30 days from the end of palliative radiotherapy, correlated to tumour stage |
F_5 | Percentage of patients requiring hospitalisation due to complications after surgical treatment |
F_6 | Percentage of patients requiring hospitalisation due to complications after radiotherapy |
F_7 | Percentage of patients requiring hospitalisation due to complications after systemic treatment |
F_8 | Percentage of patients who received chemotherapy during inpatient hospitalisation |
F_9 | Percentage of stage III and IV cancer patients |
F_10 | Assessment of the completeness of a pathological exam |
F_11_1 | Percentage of patients with genetic and molecular testing for predictive factors (colorectal cancer) |
F_11_2 | Percentage of patients with genetic and molecular testing for predictive factors (lung cancer) |
F_11_3 | Percentage of patients with genetic and molecular testing for predictive factors; immunohistochemistry only (breast cancer) |
F_11_4 | Percentage of patients with genetic and molecular testing for predictive factors (breast cancer) |
F_11_5 | Percentage of patients with genetic and molecular testing for predictive factors; FISH only (breast cancer) |
F_11_6 | Percentage of patients with genetic and molecular testing for predictive factors (ovarian cancer) |
F_11_7 | Percentage of patients with genetic and molecular testing for predictive factors; immunohistochemistry only (DCIS) |
F_11_8 | Percentage of patients with genetic and molecular testing for predictive factors (DCIS) |
F_12_1 | The percentage of surgical procedures performed with minimally invasive surgery (colorectal cancer) |
F_12_2 | The percentage of surgical procedures performed with minimally invasive surgery (lung cancer) |
F_12_3 | The percentage of surgical procedures performed with minimally invasive surgery (ovarian cancer) |
F_12_4 | The percentage of surgical procedures performed with minimally invasive surgery (prostate cancer) |
F_13 | Median time elapsed from the date of registration of the patient for a diagnostic (imaging or pathomorphological) exam to the date of obtaining the result of this exam |
F_14 | Percentage of repeated diagnostic tests over a 6-week period (computed tomography, endoscopy, biopsy, pathomorphological assessment, molecular assessment), shown for each participating centre by tumour type and test type |
F_15 | Percentage of repeated surgical treatments fordiagnoses other thanbreast cancer |
F_16 | Percentage of patients with rectal cancer who received preoperative radiotherapy |
F_17 | Proportion of postoperative histopathology assessment in patients with colorectal cancer with at least 12 lymph nodes assessed |
F_18 | The rate of anastomotic leakage in colon and rectal cancer |
F_19 | Assessment of the number of lymph nodes removed during prostatectomy |
F_20 | The percentage of pelvic lymphadenectomy performedaccording to anatomical ranges |
F_21 | Amounts of positive postoperative margins after prostatectomy |
F_22 | Percentage of patients with suspected lung cancer consulted by a pulmonologist within 14 working days from the date of registering the referral with the service provider |
F_23 | The proportion of patients with mediastinal lymphadenopathy greater than 10 mm who underwent EBUS-TBNA |
F_24 | The proportion of patients with suspected lung cancer and pleural effusion diagnosed with fluid aetiology |
F_25 | The proportion of patients with stage III non-small-cell lung cancerwho received concurrent chemoradiotherapy |
F_26 | The proportion of ovarian cancer patients treated with primary optimal or suboptimal cytoreduction (no residual mass or ≤ 1 cm) |
F_27 | The proportion of patients with ovarian cancer who received neoadjuvant chemotherapy |
F_28 | Percentage of patients with ovarian cancer who underwent exploratory laparotomy |
F_29 | The proportion of patients with non-infiltrating breast neoplasms not larger than 2 cm in diameter (excluding patients with BRCA1 and BRCA2 mutations) undergoing breast-conserving therapy |
F_30 | The proportion of patients with infiltrative breast neoplasm not exceeding 3 cm in diameter (total size, including the DCIS component; after excluding patients with BRCA1 and BRCA2 mutations) undergoing breast-conserving treatment |
F_31 | Percentage of diagnostic tests requiring redescription orreverification of the material over a 6-week period (computedtomography, pathomorphological assessment, molecular assessment),shown for each participating centre by tumour type and test type |
F_32 | Percentage of DCIS breast patients with no axillary lymphadenectomy |
F_33 | The proportion of patients with invasive breast neoplasm withoutlymph node metastases (pN0) without axillary lymphadenectomy |
F_34 | Percentage of patients with ER-positive and PR-positive infiltrating breast cancer who received hormone therapy |
F_35 | The percentage of patients with inflammatory or locally advanced, unresectable breast cancer |